Literature DB >> 11469670

Major system toxicities and side effects of anticonvulsants.

A C Swann1.   

Abstract

The use of anticonvulsants is expanding in the treatment of bipolar and related disorders. Although they have characteristics in common, the anticonvulsants currently used are quite diverse and vary in their spectrum of activity, quality of supporting evidence, and organ toxicities. Common side effects of anticonvulsants that can limit tolerability but are not physiologically severe include sedation and other cognitive impairments, tremor, and gastrointestinal side effects. Possibly less common, but of more physiologic significance, are effects on body weight and metabolism and dose-related hepatic and hematologic effects. Severe, but rare, toxicities include skin, bone marrow, and hepatic toxicity due to hypersensitivity. The most important aspect of successful management of severe toxicities is early detection, discontinuation of the medicine, and vigorous treatment of the toxicity. Anticonvulsants can also be associated with fetal toxicity, especially neural tube defects. In general, anticonvulsants are well tolerated and their effectiveness greatly outweighs risk or annoyance from side effects, but side effects must be kept in mind when choosing and monitoring treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469670

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

Review 1.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 2.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

3.  The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.

Authors:  Andrew Lloyd; Emma McIntosh; Martin Price
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

5.  Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.

Authors:  Staci Martin; Shawn Nelson Schmitt; Pamela L Wolters; Brittany Abel; Mary Anne Toledo-Tamula; Andrea Baldwin; Rikard K Wicksell; Melinda Merchant; Brigitte Widemann
Journal:  Pain Med       Date:  2014-11-06       Impact factor: 3.750

6.  Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis.

Authors:  James D Doorley; Jonathan Greenberg; Jafar Bakhshaie; Nathan S Fishbein; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2021-08-19       Impact factor: 4.506

7.  [Risk assessment in pain therapy].

Authors:  D Schoeffel; H R Casser; M Bach; H G Kress; R Likar; H Locher; W Steinleitner; M Strohmeier; H Brunner; R D Treede; W Zieglgänsberger; J Sandkühler
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

8.  Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy.

Authors:  Azim Honarmand; Mohammadreza Safavi; Mohammad Zare
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

9.  Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.

Authors:  Julie M Zito; Albert T Derivan; Christopher J Kratochvil; Daniel J Safer; Joerg M Fegert; Laurence L Greenhill
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-09-15       Impact factor: 3.033

10.  Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities.

Authors:  Kimberly D McLaren; Lauren B Marangell
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-04-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.